Raymond James Initiates Coverage on Xilio Therapeutics with Outperform Rating

Raymond James has initiated coverage on Xilio Therapeutics, Inc. (ticker: XLO) with an 'Outperform' rating. The firm has set a price target of $16.00 per share for the company's stock.